Scilex Holding (SCLX) Other Accumulated Expenses (2020 - 2026)
Scilex Holding (SCLX) recorded quarterly Other Accumulated Expenses of $255000.0 in Q1 2026, down 99.89% quarter-over-quarter from $231.8 million in Q4 2025, and down 99.85% on a YoY basis from $168.4 million in Q1 2025.
Scilex Holding (SCLX) Other Accumulated Expenses (2020 - 2026) Analysis & Trends
Scilex Holding's Other Accumulated Expenses history runs 7 years deep, the most recent figure standing at $255000.0 for Q1 2026.
- In Q1 2026, Other Accumulated Expenses fell 99.85% year-over-year to $255000.0; the TTM figure through Mar 2026 stood at $255000.0 (down 99.85% YoY), while the FY2025 annual figure was $231.8 million, changed N/A from the prior year.
- Other Accumulated Expenses was $255000.0 for Q1 2026 at Scilex Holding, down from $231.8 million in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $231.8 million in Q4 2025 to a low of $255000.0 in Q1 2026.
- Historically, Other Accumulated Expenses has averaged $93.4 million across 5 years, with a median of $89.7 million in 2023.
- The sharpest annual moves came in 2024 and 2026: Other Accumulated Expenses soared 984.25% in 2024, then plunged 99.85% in 2026.
- A 5-year view of Other Accumulated Expenses shows it stood at $30.9 million in 2022, then surged by 190.22% to $89.7 million in 2023, then jumped by 58.06% to $141.7 million in 2024, then jumped by 63.54% to $231.8 million in 2025, then tumbled by 99.89% to $255000.0 in 2026.
- The last three Other Accumulated Expenses figures came in at $255000.0 (Q1 2026), $231.8 million (Q4 2025), and $5.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn |
| 10 | Scilex Holding | 48.31 Mn | -101.62 Mn | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 255,000.00 |
| Dec 31, 2025 | 231.76 Mn |
| Sep 30, 2025 | 5.74 Mn |
| Jun 30, 2025 | 192.94 Mn |
| Mar 31, 2025 | 168.43 Mn |
| Sep 30, 2024 | 141.71 Mn |
| Jun 30, 2024 | 125.06 Mn |
| Mar 31, 2024 | 104.09 Mn |
| Dec 31, 2023 | 89.66 Mn |
| Sep 30, 2023 | 65.80 Mn |
| Jun 30, 2023 | 47.78 Mn |
| Mar 31, 2023 | 9.60 Mn |
| Dec 31, 2022 | 30.89 Mn |
| Dec 31, 2021 | 7.36 Mn |
| Dec 31, 2020 | 25,760.00 |